Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein:<i>in silico</i>studies
Aaftaab Sethi, Swetha Sanam, Sharon Munagalasetty, Sivaraman Jayanthi, Mallika Alvala
Abstract
testing of galectin inhibitors against SARS-CoV-2. In addition, it warrants a swift examination of TD-139 for treating COVID-19.
Topics & Concepts
In silicoDocking (animal)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Computational biologyVirusSpike ProteinIn vitroCoronavirus disease 2019 (COVID-19)In vivoBinding siteChemistryBiologyVirologyMedicineBiochemistryInfectious disease (medical specialty)DiseaseGeneticsPathologyGeneNursingGalectins and Cancer BiologyToxin Mechanisms and ImmunotoxinsCancer Mechanisms and Therapy